Mental disorder | Cumulative incidence (in %)† |
---|---|
Any mental illness (Nordentoft, et al., 2011) | ♂: 4.33 ♀: 2.10 |
Schizophrenia (Nordentoft, et al., 2011) | ♂: 6.55 ♀: 4.91 |
Schizophrenia spectrum disorders (Nordentoft, et al., 2011) | ♂: 5.90 ♀: 4.07 |
Depression* (Aaltonen, et al., 2018) | ♂: 8.64 ♀: 4.14 |
Bipolar affective disorder* (Nordentoft, et al., 2011) | ♂: 7.77 ♀: 4.78 |
Unipolar affective disorder* (Nordentoft, et al., 2011) | ♂: 6.67 ♀: 3.77 |
Substance abuse at psychiatric department (Nordentoft, et al., 2011) | ♂: 4.71 ♀: 3.34 |
Substance abuse at somatic hospital (Nordentoft, et al., 2011) | ♂: 2.54 ♀: 1.71 |
Anorectic disorder (Nordentoft, et al., 2011) | ♂: 5.61 ♀: 2.62 |
Acute stress reaction (Gradus, et al., 2015) | 0.63 |
Adjustment disorder (Gradus, et al., 2015) | 0.78 |
PTSD (Gradus, et al., 2015) | 0.61 |
Disorder | Risk estimate (95% CI)‡ | Adjusted for |
---|---|---|
Acute stress reaction (Petersen, et al., 2020) | IRR= 24 (10–53) | †† |
ADHD (Ljung, et al., 2014) | OR= 5.9 (2.5–14.3) | ††† |
ADHD (Fitzgerald, et al., 2019) | IRR= 1.6 (1.2–2.3) | ††† |
Adjustment disorder (Petersen, et al., 2020) | IRR= 12 (9.8–15) | †† |
Alcohol abuse or dependence (Tidemalm, et al., 2008) | ♂: HR= 1.1 (1.0–1.3) ♀: HR= 1.7 (1.3–2.1) | †† |
Alcohol use disorder (Qin, 2011) | ♂: IRR= 8.2 (7.5–8.9) ♀: IRR= 24.1 (20.5–28.4) | †† |
Anxiety disorder (Tidemalm, et al., 2015) | ♂: HR= 1.9 (1.5–2.3) ♀: HR= 1.5 (1.3–1.9) | †† |
Autism spectrum disorder (Kõlves, et al., 2021) | IRR= 2.1 (1.8–2.1) | †† |
Bipolar and unipolar disorder (Tidemalm, et al., 2008) | ♂: HR= 3.5 (3.0–4.2) ♀: HR= 2.5 (2.1–3.0) | †† |
Bipolar disorders (Qin, 2011) | ♂: IRR= 11.5 (9.3–14.2) ♀: IRR= 26.5 (21.5–32.5) | †† |
Borderline personality disorders (Qin, 2011) | ♂: IRR= 16.6 (13.0–21.2) ♀: IRR= 55.5 (40.9–75.3) | †† |
Drug abuse or dependence (Tidemalm, et al., 2008) | ♂: HR= 1.6 (1.1–2.2) ♀: HR= 2.3 (1.6–3.3) | †† |
Drug use disorders (Qin, 2011) | ♂: IRR= 10.7 (9.0–12.7) ♀: IRR= 26.1 (21.2–32.1) | †† |
Obsessive–compulsive disorder (De La Cruz, et al., 2017) | OR= 7.5 (6.6–8.5) | ††† |
Other affective disorder (Qin, 2011) | ♂: IRR= 15.9 (14.2–17.9) ♀: IRR= 19.9 (17.8–22.2) | †† |
Other anxiety disorders (Qin, 2011) | ♂: IRR= 7.2 (5.4–9.6) ♀: IRR= 9.8 (7.9–12.2) | †† |
Other depressive disorder (Tidemalm, et al., 2008) | ♂: HR= 1.4 (1.2–1.6) ♀: HR= 1.7 (1.5–1.9) | †† |
Other personality disorders (Qin, 2011) | ♂: IRR= 8.3 (7.5–9.2) ♀: IRR= 19.0 (17.0–21.2) | †† |
Other psychiatric disorders (Qin, 2011) | ♂: IRR= 5.8 (5.2–6.6) ♀: IRR= 12.9 (11.4–14.6) | †† |
Other schizophrenic disorders (Qin, 2011) | ♂: IRR= 11.7 (10.2–13.4) ♀: IRR= 17.5 (15.0–20.3) | †† |
Personality disorder (Tidemalm, et al., 2008) | ♂: HR= 1.8 (1.4–2.3) ♀: HR= 1.5 (1.1–2.1) | †† |
PTSD (Petersen, et al., 2020) | IRR= 13 (4.3–42) | †† |
PTSD (Fox, et al., 2021) | ♂: HR= 1.7 (1.3–2.1) ♀: HR= 2.6 (2.2–3.1) | ††† |
Reaction to stress/adjustment disorders (Qin, 2011) | ♂: IRR= 15.5 (13.9–17.3) ♀: IRR= 22.8 (19.9–26.0) | †† |
Recurrent depression (Qin, 2011) | ♂: IRR= 21.4 (19.0–24.0) ♀: IRR= 29.7 (26.7–33.0) | †† |
Schizophrenia (Tidemalm, et al., 2008) | ♂: HR= 4.1 (3.5–4.8) ♀: HR= 3.5 (2.8–4.4) | †† |
Schizophrenia (Qin, 2011) | ♂: IRR= 9.5 (8.4–10.7) ♀: IRR= 19.3 (16.3–22.7) | †† |
Physical disorder | Risk estimate (95% CI) ‡ | Adjusted for |
---|---|---|
Excess risks: | ||
Fibromyalgia (Dreyer, et al., 2010) | SMR= 10.5 (4.5–20.7) | † |
ALS (Erlangsen, et al., 2020b) | IRR= 4.9 (3.5–6.9) | ††† |
Huntington disease (Erlangsen, et al., 2020b) | IRR= 4.9 (3.1–7.7) | ††† |
Cardiac arrest with successful resuscitation (Petersen, et al., 2020) | IRR= 4.8 (3.6–6.3) | ††† |
Cardiovascular diseases (Sariaslan, et al., 2022) | HR=3.3 (2.7–4.1) | ††† |
Cancer (Fang, et al., 2012) | IRR=3.1 (2.7–3.5) | †† |
Diabetes (Sariaslan, et al., 2022) | HR=3.1 (2.3–4.2]) | ††† |
Diabetes (insulin-treated only (Niskanen, et al., 2018) | ♂: OR=2.8 (2.0, 3.8) ♀: OR=1.8 (0.9, 3.4) | †† |
Chronic respiratory diseases (Sariaslan, et al., 2022) | HR=2.7 (2.1–3.4) | ††† |
Guillain-Barré (Erlangsen, et al., 2020b) | IRR= 2.2 (1.2–4.1) | ††† |
Multiple sclerosis (Erlangsen, et al., 2020b) | IRR= 2.2 (1.9–2.6) | ††† |
Diseases of myoneural junction and muscle (Erlangsen, et al., 2020b) | IRR= 1.9 (1.8–2.1) | ††† |
Head injury/Traumatic brain injury (Madsen, et al., 2018) | IRR= 1.9 (1.8–2.0) | ††† |
Other brain disorders (Erlangsen, et al., 2020b) | IRR= 1.8 (1.5–2.1) | ††† |
Polyneuropathy and peripheral neuropathy (Erlangsen, et al., 2020b) | IRR= 1.7 (1.6–1.8) | ††† |
Epilepsy (Erlangsen, et al., 2020b) | IRR= 1.7 (1.6–1.8) | ††† |
Parkinson disease (Erlangsen, et al., 2020b) | IRR= 1.7 (1.5–1.9) | ††† |
Encephalitis (Erlangsen, et al., 2020b) | IRR= 1.7 (1.3–2.3) | ††† |
Lyme Borreliosis (Fallon, et al., 2021) | IRR=1.7 (1.2–2.6) | ††† |
Ulcerative coliti (Gradus, et al., 2010) | OR = 1.7 (1.3–2.1) | ††† |
Sleep disorders (Kjaer Hoier, et al., 2022) | ♂: IRR=1.6 (1.4–1.7) ♀: IRR=2.2 (1.8–2.6) | ††† |
Meningitis (Erlangsen, et al., 2020b) | IRR= 1.6 (1.2–2.0) | ††† |
Crohn’s disease (Gradus, et al., 2010) | OR= 1.6 (1.1–2.3) | ††† |
CNS infection (Erlangsen, et al., 2020b) | IRR= 1.6 (1.3–1.9) | ††† |
Any heart disease (Petersen, et al., 2020) | IRR=1.5 (1.5–1.6) | ††† |
Heart failure (Petersen, et al., 2020) | IRR= 1.5 (1.4–1.6) | ††† |
Atrial fibrillation and flutter (Petersen, et al., 2020) | IRR=1.4 (1.3–1.5), | ††† |
Tinnitus (Mølhave, et al.) | IRR=1.4 (1.2–1.6) | ††† |
Intracerebral hemorrhage (Erlangsen, et al., 2020b) | IRR= 1.4 (1.1–1.6) | ††† |
Cerebral infarction (Erlangsen, et al., 2020b) | IRR=1.3 (1.1–1.6) | ††† |
Acute myocardial infarction (Petersen, et al., 2020) | IRR= 1.3 (1.2–1.4) | ††† |
Stroke (Erlangsen, et al., 2020b) | IRR: 1.3 (1.2–1.3) | ††† |
Inflammatory bowel disease (Ludvigsson, et al., 2021) | HR=1.2 (1.1–1.4) | † |
Visual impairment (Meyer-Rochow, et al., 2015) | SMR= 1.3 (1.1–1.6) | † |
Hashimoto’s (Heiberg Brix, et al., 2019)thyroiditis | HR=1.3 (>1.0–1.6) | ††† |
Angina pectoris (Petersen, et al., 2020) | IRR= 1.2 (1.1–1.3) | ††† |
Allergy (air pollen counts of 30–100 (Qin, et al., 2013) | RR=1.1 (1.1–1.2) | †† |
Chronic pain (Vaegter, et al., 2019) | SMR=7.3 (2.7–15.9) | † |
Infection (Lund-Sørensen, 2016) | IRR=1.4 (1.4–1.5) | ††† |
No excess risk: | ||
Organ transplant (Gradus, et al., 2019) | HR= 1.8 (0.9, 3.6) | †† |
Coeliac disease (Ludvigsson, et al., 2011) | HR = 1.4 (1.0–2.0) | ††† |
Congenital heart disease (Udholm, et al., 2020) | HR=0.8 (0.5–1.4) | † |
Lower risk: | ||
Alzheimer disease (Erlangsen, et al., 2020b) | IRR=0.2 (0.2–0.3) | ††† |
Intellectual disabilites (Erlangsen, et al., 2020b) | IRR=0.6 (0.5–0.8) | ††† |
Dementia (Erlangsen, et al., 2020b) | IRR=0.8 (0.7–0.9) | ††† |
Stressful life-events |
---|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|